vaccine, varicella-zoster


Merck Sharp & Dohme


Zuellig Pharma
Concise Prescribing Info
Live attenuated varicella virus (Oka/Merck strain)
Vaccination against varicella in individuals ≥12 mth.
Dosage/Direction for Use
Adult & adolescent ≥ 13 yr Two 0.5-mL SC inj 4-8 wk apart. Childn 12 mth-12 yr 0.5-mL SC inj as single dose.
Hypersensitivity to any component including gelatin. History of anaphylactoid reaction to neomycin. Blood dyscrasias, leukemia, lymphoma, malignant neoplasms affecting bone marrow or lymphatic system. Immunosuppressive therapy. Primary & acquired immunodeficiency. Family history of congenital or hereditary immunodeficiency. Active untreated TB, febrile resp illness or other active infections. Pregnancy.
Special Precautions
Do not inject intravascularly. Defer vaccination for at least 5 mth following blood/plasma transfusion or administration of immune globulin/varicella zoster immune globulin (VZIG). Following administration of Varivax, any immune globulin including VZIG should not be given for 2 mth thereafter. Avoid salicylates for 6 wk. HIV patients w/ or w/o evidence of immunosuppression. Avoid close association w/ susceptible high-risk individuals. Avoid pregnancy for 3 mth after vaccination. Lactation. Childn <1 yr & infant <12 mth.
Adverse Reactions
Upper & lower resp illness, cough, irritability/nervousness, fatigue, disturbed sleep, diarrhea, loss of appetite, vomiting, otitis, diaper/contact rash, headache, teething, malaise, abdominal pain, other rash, nausea, eye complaints, chills, lymphadenopathy, myalgia, allergic reactions including allergic rash & hives, stiff neck, heat rash/prickly heat, arthralgia, eczema/dry skin/dermatitis, constipation, itching.
ATC Classification
J07BK01 - varicella, live attenuated ; Belongs to the class of varicella viral vaccines.
Varivax vaccine (inj) (vial) 0.5 mL
(+ diluent) 10 × 1's;1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in